Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00852943
Other study ID # 090086
Secondary ID 09-I-0086
Status Active, not recruiting
Phase
First received
Last updated
Start date November 2, 2010

Study information

Verified date March 11, 2024
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: - Mast cells are responsible for most symptoms of allergic reactions. In some allergic diseases, it is unusually easy to cause mast cells to release their contents and cause allergic reactions. In other cases, mast cells grow abnormally and, in rare cases, can result in tumors. Mast cells also control other parts of the immune system. - Understanding why mast cells behave abnormally in allergic diseases is important to finding better ways for diagnosing and treating these potentially life-threatening disorders. Objectives: - To screen mast cells at the genetic and functional levels to characterize abnormalities, identify mutations, detect carrier states, and/or develop therapies for such disorders. - To create a library of information about inherited diseases of mast cell homeostasis and activation, including piebaldism (problems with skin and hair pigmentation), anaphylaxis (severe allergic reaction), allergies, asthma, atopic dermatitis (eczema), allergic rhinitis ( hay fever ), food allergies, urticaria/angioedema (hives/swelling), immunodeficiency diseases, and autoimmune diseases. Eligibility: - Patients between the ages of 1 and 80 years who have been referred by a physician and are known to have or be suspected of having an inherited disorder of mast cells, in particular patients (and their relatives) with piebaldism, allergies, or anaphylaxis that is not caused by allergies. Design: - Study population will consist of up to 1000 participants in a 5-year period. One third of the study population will consist of patients; the other two thirds will consist of biological relatives. - Evaluation is limited to testing on blood specimens; no treatment will be provided. - Clinical and research laboratory evaluations of patients will include the following: - Clinical evaluation and previous laboratory tests as documented in outside medical records by health care providers. A standard questionnaire will also be administered at the time of subject enrollment. - Blood collection for clinical laboratory testing, tailored to each subject s clinical evaluation where appropriate (5 ml). - Blood collection for research laboratory testing, tailored to each subject s clinical evaluation including genetic screening and assessment of mast cell growth and functioning and storage of additional frozen blood specimens for future studies (up to an additional 30 ml). - Evaluations of blood relatives will include the following: - Clinical evaluation as documented from outside medical records by health care providers and administration of a standard questionnaire. - Blood collection where indicated for diagnostic or research purposes. - After 12 consecutive months on the study, results from initial evaluation will be reviewed. Subjects with findings deemed to be of continued interest will be contacted and invited to remain as active participants to this protocol for another year, provided that they renew their consent to participate.


Description:

This protocol is designed to screen subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or mast cell homeostasis and activation. Patients determined by clinical history and initial outside evaluation by their referring physician to be of interest will be consented and enrolled into this study. Blood specimens, stored blood products and derivatives, saliva, hair, fingernail clippings, cord blood, umbilical cord, and/or buccal swabs from such patients and/or their family members will be obtained for research studies related to understanding the genetic and biochemical bases of these diseases. Outside medical records may be obtained for chart review to correlate clinical history to research laboratory testing results. Results will be relayed to the referring physicians and, where applicable, patients will be referred to other appropriate NIH protocols for additional clinical evaluation and treatment. The study will enroll up to 1000 subjects and family members.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 773
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 1 Day to 99 Years
Eligibility - INCLUSION CRITERIA: - Subjects, ages birth to 99 years old, known to have or suspected of having an inherited or acquired genetic disorder resulting in severe allergic inflammation and/or reactivity associated with alterations in mast cell and/or eosinophil homeostasis or activation, will be eligible for enrollment. Because of the intensive time and labor required for research laboratory testing, subjects will be enrolled only if in the opinion of the investigator (based on discussions with the patient s private physician) there is a high index of suspicion of a genetic basis for the observed allergic manifestation(s). - Blood relatives of enrolled subjects will be eligible for enrollment. - There will be no discrimination as to age, gender, race, or disability. - Subjects must have a health care provider outside of the NIH. - Subjects must agree to have their blood stored for future studies of the immune system and/or other medical conditions. EXCLUSION CRITERIA: - Ongoing systemic immune modulation with agents such as biologics that target mast cells and eosinophils, immune modulating or cytotoxic chemotherapy, and/or malignancy may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process would interfere with evaluation.

Study Design


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Association of single gene mutations which are deemed causal with specific syndromic presentations of allergic disease, including atopic dermatitis, asthma, food allergy, eosinophilic disease, urticaria anaphylaxis, angioedema, IgE levels and ch... Association of single gene mutations which are deemed causal with specific syndromic presentations of allergic disease, including atopic dermatitis, asthma, food allergy, eosinophilic disease, urticaria anaphylaxis, angioedema, IgE levels and changes to allergy-related effector cells. end of study or until a gene is found
See also
  Status Clinical Trial Phase
Terminated NCT00527878 - Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome Phase 2
Completed NCT04643639 - Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis Phase 3
Completed NCT05256784 - Mountain Food and Natural Probiotic in Nutrition
Recruiting NCT04448951 - Immune Homeostasis in Sepsis and Septic Shock
Recruiting NCT03721146 - ENCAPSID Study : ENCApsulated Bacterial Infection and Primary, Secondary ImmunoDeficiency
Not yet recruiting NCT06089174 - Assessment of the Increased Risk of Infection Following an Ultratrail N/A
Completed NCT02895204 - Effect of Fermented Maillard Reacted Whey Protein on Immune Function N/A
Recruiting NCT03707782 - Mechanisms of Immune Deficiency
Recruiting NCT06332196 - Immunodeficiency and Cancer: Identification of Congenital Immune System Defects Underlying Paediatric Lymphomas N/A
Recruiting NCT04646525 - The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs
Completed NCT03609840 - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Not yet recruiting NCT01359384 - Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment N/A
Recruiting NCT05605808 - Aerobic Training and Diet on the Immune System in Postmastectomy Patients Receiving Chemotherapy N/A
Completed NCT03899480 - Adoptive Transfer of Haploidentical NK Cells and N-803 Phase 1
Completed NCT03051425 - Immune Benefits of Consumption of Dairy Yogurt in Elderly N/A
Active, not recruiting NCT04824651 - Covid-19 Vaccine Cohort in Specific Populations
Enrolling by invitation NCT04382508 - Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.
Completed NCT02334943 - Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment N/A
Completed NCT03052491 - Effects of a 10 Component Dietary Supplement on Health and the Quality of Life N/A
Completed NCT03881566 - Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients